Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

PARTICIPANT INCLUSION CRITERIA

Stage II-III multiple myeloma or have progression after initial treatment of Stage I disease (Durie Salmon Staging). Patients with plasma cell leukemia are also included.
Multiple myeloma / plasma cell leukemia diagnosis confirmed by pathology reviewed at Stanford University Medical Center.
18 to ≤ 75 years of age
Karnofsky Performance Status > 70%.
Corrected Carbon monoxide diffusing capacity (Dlco) > 60%
Left ventricle ejection fraction (LVEF) > 50%.
Alanine aminotransferase (ALT) ≤ 2 x normal
Aspartate aminotransferase (AST) ≤ 2 x normal
Total bilirubin ≤ 2 mg/dL, unless hemolysis or Gilbert's disease.
Estimated creatinine clearance > 50 mL/min.
Identified related or unrelated Human leukocyte antigen (HLA)-identical donor or donor with one antigen/allele mismatch in (HLA-A, B, C or DRB1).
Signed informed consent.

DONOR INCLUSION CRITERIA

At least 17 years of age
HIV-seronegative
Must be capable of giving signed, informed consent
No contraindication to the administration of filgrastim
Willing to have a central venous catheter placed for apheresis if peripheral veins are inadequate

PARTICIPANT EXCLUSION CRITERIA

Prior allogeneic hematopoietic cell transplantation
Uncontrolled active infection
Uncontrolled congestive heart failure or angina
HIV-positive
Pregnant or nursing

DONOR EXCLUSION CRITERIA

Serious medical or psychological illness
Pregnant or lactating
Prior malignancies within the last 5 years except for non-melanoma skin cancers